BME:PHMBiotechs
Assessing Pharma Mar (BME:PHM) Valuation After Zepzelca Milestones And Strong 2025 Growth Update
Pharma Mar (BME:PHM) has drawn fresh attention after its 2025 results update, with management pointing to 27% revenue growth, a fivefold jump in EBITDA, and key regulatory progress for oncology drug Zepzelca.
See our latest analysis for Pharma Mar.
The share price has risen over recent months, with a 30 day share price return of 6.73% and a 90 day return of 7.72%. However, the 1 year total shareholder return is a 9.03% decline and the 3 year total shareholder return is 83.97%, suggesting...